Johnson & Johnson (JNJ) Q1 results: Revenues: $20,009M (+12.6%); Consumer: $3,398M (+5.3%); Pharmaceutical: $9,844M (+19.4%); Medical Devices: $6,767M (+7.5%).

Net Income: $4,367M (-1.2%); EPS: $1.60 (-0.6%); Non-GAAP EPS: $2.06 (+12.6%).

Sales by Business: Baby Care: $457M (+0.4%); Beauty: $1,084M (+10.5%); Oral Care: $379M (+4.7%); Women’s Health: $243M (+0.4%); Immunology: $3,042M (+3.8%); Infectious Diseases: $830M (+10.8%); Neuroscience: $1,559M (+4.1%); Oncology: $2,311M (+45.0%); Cardiovascular / Metabolism / Other: $1,517M (+2.8%).

Key Product Sales: REMICADE: $1,389M (-16.9%); SIMPONI / SIMPONI ARIA: $518M (+21.0%); STELARA: $1,061M (+28.9%); DARZALEX: $432M (+69.4%); XARELTO: $578M (+12.7%); ZYTIGA: $845M (+61.6%).

2018 Guidance: Revenues: $81B – $81.8B; Non-GAAP EPS: $8.00 – $8.20.

Shares are up 1% premarket.



READ SOURCE

MUST READ  Oasis Midstream Partners LP EPS of $0.02
SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here